特定进化枝的HIV-1整合酶多态性不会降低拉替拉韦和埃替拉韦的表型敏感性。
Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.
作者信息
Van Baelen Kurt, Van Eygen Veerle, Rondelez Evelien, Stuyver Lieven J
机构信息
Virco BVBA, Generaal De Wittelaan L11 B4, 2800Mechelen, Belgium.
出版信息
AIDS. 2008 Sep 12;22(14):1877-80. doi: 10.1097/QAD.0b013e32830f9703.
The contribution of clade-specific polymorphisms in the HIV-1 integrase gene towards integrase inhibitor phenotypic susceptibility was tested on 137 clinical isolates, of which 60 were non-clade B strains. Control Q148R mutant virus showed fold change values of 17.85 +/- 2.77 and 88.94 +/- 9.02 for raltegravir and elvitegravir, respectively, whereas the average fold change for the clinical samples was 0.91 +/- 0.40, and 0.84 +/- 0.37. Phenotypic testing proved that clade-specific integrase polymorphisms do not contribute to reduced susceptibility towards integrase inhibitors.
在137株临床分离株上测试了HIV-1整合酶基因中特定分支多态性对整合酶抑制剂表型敏感性的影响，其中60株为非B分支菌株。对照Q148R突变病毒对raltegravir和elvitegravir的倍数变化值分别为17.85±2.77和88.94±9.02，而临床样本的平均倍数变化为0.91±0.40和0.84±0.37。表型测试证明，特定分支的整合酶多态性不会导致对整合酶抑制剂的敏感性降低。
Zotero 插件